Search results for "Biopharmaceutical industry"
showing 10 items of 17 documents
An alliance timing game under real options in biopharmaceutical industry
2014
The importance of alliances in firm capital structure decisions: evidence form biotechnology firms
2017
Building on finance research, we argue that the ex post hazards arising from alliance formation depend upon the firm’s financial condition. Financial distress jeopardizes the continuity of an alliance and the value of the investments involved. Thus, firms should reduce leverage to signal continued commitment and to induce investments from alliance partners. Accordingly, we find that a firm’s current alliance propensity predicts its subsequent capital structure decisions and that this relationship is most pronounced in the presence of other exchange hazards. Our paper contributes to alliance research and to the growing literature discussing the strategic consequences of capital structure.
A real options game of alliance timing decisions in biopharmaceutical research and development
2017
Abstract In this article we examine the alliance timing trade-off facing both pharmaceutical and biotech firms in a stochastic and competitive environment. Specifically, we introduce a real options game (ROG), where a pharmaceutical company can choose between two competing biotech firms by sequentially offering a licensing deal early or late in the new drug development process. We find that, when the alliance raises the drug market value significantly, the agreement is signed late in the drug development process. This suggests that the postponement effect implied by the use of real options prevails over the biotech firms’ competition effect, which would instead play in favor of an early agr…
The interaction between inter-firm and interlocking directorate networks on firm's new product development outcomes
2016
This paper explores the interaction between a prominent board of directors and the network of inter-firm rela- tionships on new product development. Specifically, we posit a positive interaction effect between a prominent board and the inter-firm network and structural holes positions on the number of new products developed by the firm. We test the theoretical framework on a sample of 1758 agreements among 1890 biopharmaceutical firms over the period 2006–2010. We find that by filtering, complementing and legitimizing information coming from the inter-firm network, a prominent interlocking directorate network can improve the inter-firm network's effects on new product development. We discus…
Network Positions and the Probability of Being Acquired: An Empirical Analysis in the Biopharmaceutical Industry
2016
This paper examines the relationship between the firm's direct ties, its inter-firm network prominence and its likelihood of being acquired. The authors argue that firm's direct ties and prominence enhance the firm's visibility and signal its quality – and thus foster the firm's likelihood of being acquired. However, higher levels of direct ties and prominence, by providing access to resources and the firm's status, respectively, increase the firm's ability to remain independent and thus reduce its likelihood of being acquired. Thus, the authors posit the overall relation as an inverted U-shaped. Furthermore, they show that, for firms that undergo an initial public offering, the aforementio…
A real options based support system to open innovation
2012
Pharmaceutical R&D process (PR&DP) has been deeply investigated by different streams of literature; the interest is due to the strategic implication of the related decisions undertaken. The PR&DP has been revolutionised by the biotech advent and as a consequence R&D managers cannot avoid to consider Open Innovation paradigm during this decision process. Starting from a Real Option optimization model available in literature, the paper aims at proposing a decision support system (DSS) able to suggest the candidate products to be included in the best R&D portfolio varying input parameters (resilient products), to provide a products Pareto analysis that aims at individuating the products for wh…
Open innovation and firms performance: state of the art and empirical evidences from the bio-pharmaceutical industry
2016
The research presented in this paper explores the effect of inbound, outbound and coupled open innovation practices on firms' performances in the biopharmaceutical industry. Specifically, although existing researches on open innovation effectiveness have separately investigated the effect of open innovation practices on innovation and financial performance, this study evaluates the concurrent effect of these practices on both such performance dimensions in a single framework. We state the importance for a manager to explore concurrently the influence of specific open innovation practices both on innovation and economic-financial performance. We empirically test our framework on a sample of …
How strategic needs influence alliance formation and their governance modes: An empirical study in the Italian biopharmaceutical industry
2011
Firms enter strategic alliances for various reasons, and the motives behind formation of these alliances are one of main research subjects in the management field. The large literature on the issue has highlighted how alliances answer to a strategic need for collaboration that is the need to improve competitive strength through collaboration agreements. However, the study here addresses the strategic need perspective to alliances under a more specific point of view. We question what kind of competitive strengths firms aim at acquiring through inter-firm relationships. By reviewing of the most relevant literature on the issue we assume that alliances respond to three principal strategic need…
Governance forms drivers in bio-pharmaceutial inter-firm relationships
2012
Networking benefits are acknowledged by many studies in the industrial organization and strategic management fields; transaction cost theory agency and property right theory provide the economic foundations to the market-hierarchy dilemma; while Resource based-view (RBV), relational and evolutionary theories provide the strategic foundation of the inter-firm relationships. All this theoretical strands investigate reasons that push firms to formalize their relationship in different governance structures. The bio-pharmaceutical industry has the characteristics to offer to the potential partners both exploitation or exploration alliances benefits. In particular some elements play a “pivot” rol…
The concurrent effect of Open Innovation practices on both innovation and financial performance: empirical evidences from bio-pharmaceutical industry
2012
Purpose – The research presented in this paper explores the effect of Open Innovation on firm performance in the biopharmaceutical industry. Specifically, although existing researches on Open Innovation effectiveness have separately investigated the effect of Open Innovation practices on innovation and financial performance, this study evaluates the concurrent effect of these practices on both such performance dimensions in a single framework. Design/methodology/approach – We measure firm performance and Open Innovation activities of companies listed on NASDAQ; specifically, the study focuses on 128 companies listed in the NASDAQ Biotechnology Index. This industry provides an ideal context …